Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

5,095JPY
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
¥5,095
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,406,749
52-wk High
¥6,693
52-wk Low
¥4,898

Latest Key Developments (Source: Significant Developments)

Shire Rejects Third Proposal From Takeda To Buy Out Co
8:45am EDT 

April 19 (Reuters) - Shire Plc ::NOTES ANNOUNCEMENT MADE BY TAKEDA.BOARD HAS SINCE RECEIVED TWO FURTHER PROPOSALS.SECOND PROPOSAL COMPRISED £28.75 PER SHARE IN NEW TAKEDA SHARES, TO BE LISTED IN JAPAN AND IN US; £16.75 PER SHARE IN CASH.SECOND DEAL PROPOSAL REPRESENTS A POTENTIAL VALUE OF £45.50 PER SHARE.SECOND DEAL PROPOSAL REPRESENTS A POTENTIAL VALUE OF APPROXIMATELY £43 BILLION FOR TOTAL ISSUED AND TO BE ISSUED SHARE CAPITAL OF COMPANY.UNDER SECOND PROPOSAL, BASED ON TAKEDA'S CURRENT MARKET CAP, SHIRE SHAREHOLDERS WOULD OWN APPROXIMATELY 51 PER CENT. OF ENLARGED TAKEDA.THIRD PROPOSAL ALSO COMPRISED £28.75 PER SHARE IN NEW TAKEDA SHARES, TO BE LISTED IN JAPAN AND IN US THROUGH AN ADR LISTING, AND £17.75 PER SHARE IN CASH.BASED ON TAKEDA'S CURRENT MARKET CAPITALISATION, UNDER THIRD PROPOSAL SHIRE SHAREHOLDERS WOULD OWN APPROXIMATELY 51 PER CENT.BOARD MET AGAIN AND THOROUGHLY CONSIDERED THIRD PROPOSAL WITH ITS ADVISERS, UNANIMOUSLY REJECTED IT, CONCLUDING THAT IT CONTINUES TO SIGNIFICANTLY UNDERVALUE CO.THIRD PROPOSAL REPRESENTS POTENTIAL VALUE OF £46.50 PER SHARE, ABOUT £44 BILLION FOR TOTAL ISSUED AND TO BE ISSUED SHARE CAPITAL OF COMPANY.SHIRE'S ADVISERS ENTERED INTO A DIALOGUE WITH TAKEDA'S ADVISERS TO DISCUSS WHETHER A FURTHER, MORE ATTRACTIVE, PROPOSAL MAY BE FORTHCOMING.  Full Article

Takeda Says Shire Rejected Revised Proposal of 46.50 Pounds Per Share
8:04am EDT 

April 19 (Reuters) - TAKEDA PHARMACEUTICAL CO LTD::TAKEDA - TAKEDA WAS NOTIFIED THAT BOARD OF SHIRE HAD REJECTED ITS PROPOSAL .TAKEDA PHARMACEUTICAL CO LTD - TAKEDA STATEMENT REGARDING SHIRE PLC.TAKEDA PHARMACEUTICAL CO LTD - CONFIRMS THAT ON APRIL 12 IT MADE A REVISED PROPOSAL TO BOARD OF SHIRE.TAKEDA - DISCUSSIONS BETWEEN PARTIES REGARDING A POTENTIAL OFFER ARE ONGOING.TAKEDA PHARMACEUTICAL CO LTD - REVISED PROPOSAL TO BOARD OF SHIRE TO ACQUIRE SHARE CAPITAL OF SHIRE FOR A PRICE EQUIVALENT TO £46.50 PER SHARE.TAKEDA PHARMACEUTICAL CO LTD - REVISED PROPOSAL TO BOARD OF SHIRE COMPRISED OF £17.75 IN CASH (TO BE PAID IN US$) AND £28.75 OF NEW TAKEDA SHARES..TAKEDA - PROPOSAL DOES NOT CONSTITUTE AN OFFER OR IMPOSE ANY OBLIGATION ON TAKEDA TO MAKE AN OFFER, NOR DOES IT EVIDENCE A FIRM INTENTION TO MAKE AN OFFER.TAKEDA PHARMACEUTICAL CO LTD - TAKEDA INTENDS TO MAINTAIN ITS WELL-ESTABLISHED DIVIDEND POLICY AND INVESTMENT GRADE CREDIT RATING.TAKEDA - TAKEDA WAS SUBSEQUENTLY NOTIFIED THAT BOARD OF SHIRE HAD REJECTED ITS PROPOSAL.  Full Article

Takeda Pharmaceutical to sell Brazil-based pharmaceuticals unit
Wednesday, 4 Apr 2018 09:48pm EDT 

April 5 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says co plans to sell a Brazil-based wholly owned pharmaceuticals unit Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda and unit related assets to Novamed Fabricação de Produtos Farmacêuticos Ltda. in June, at an undisclosed price .  Full Article

European Commission Approves Adcetris For CD30-Positive Cutaneous T-Cell Lymphoma
Monday, 22 Jan 2018 08:00am EST 

Jan 22 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::EUROPEAN COMMISSION APPROVES ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA AFTER ONE PRIOR SYSTEMIC THERAPY– PROVIDING AN INNOVATIVE TREATMENT OPTION TO PATIENTS.TAKEDA PHARMACEUTICAL- PHASE 3 ALCANZA STUDY DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENT IN RATE OF OBJECTIVE RESPONSE LASTING ATLEAST 4 MONTHS.TAKEDA PHARMACEUTICAL CO LTD - EUROPEAN COMMISSION EXTENDED CURRENT CONDITIONAL MARKETING AUTHORIZATION OF ADCETRIS.TAKEDA PHARMACEUTICAL- EC APPROVED ADCETRIS FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA AFTER AT LEAST 1 PRIOR SYSTEMIC THERAPY.  Full Article

Arcturus Announces Expansion Of Collaboration With Takeda
Wednesday, 17 Jan 2018 07:00am EST 

Jan 17 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES EXPANSION OF COLLABORATION WITH TAKEDA PHARMACEUTICALS TO DEVELOP RNA-BASED THERAPEUTICS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) AND OTHER GI DISORDERS.ARCTURUS THERAPEUTICS - TAKEDA, CO TO DEVELOP RNA-BASED THERAPEUTICS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, OTHER GASTROINTESTINAL.ARCTURUS - TO DEVELOP TREATMENT OF NASH AND GI RELATED DISORDERS USING CO'S LUNAR LIPID-MEDIATED DELIVERY SYSTEMS & UNA OLIGOMER CHEMISTRY.  Full Article

Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases
Friday, 5 Jan 2018 07:00am EST 

Jan 5 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA AND DENALI THERAPEUTICS COLLABORATE TO DEVELOP AND COMMERCIALIZE THERAPIES FOR NEURODEGENERATIVE DISEASES.DENALI THERAPEUTICS - TAKEDA TO MAKE AN INITIAL PAYMENT TO CO OF $150 MILLION THROUGH COMBINATION OF CASH UPFRONT PAYMENTS AND PURCHASE OF DENALI EQUITY.DENALI THERAPEUTICS - TO BE RESPONSIBLE FOR DEVELOPMENT ACTIVITIES AND COSTS PRIOR TO IND FILING FOR EACH OF THREE PROGRAMS.DENALI - WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS, INCLUDING $90 MILLION IN PRECLINICAL MILESTONES & OPT-IN PAYMENTS.DENALI THERAPEUTICS - COLLABORATION AGREEMENT TO DEVELOP,COMMERCIALIZE UP TO 3 SPECIFIED THERAPEUTIC PRODUCT CANDIDATES FOR NEURODEGENERATIVE DISEASES.DENALI - TAKEDA, CO WILL JOINTLY COMMERCIALIZE PRODUCTS IN U.S., CHINA, TAKEDA WILL HAVE EXCLUSIVE COMMERCIALIZATION RIGHTS IN ALL OTHER MARKETS.DENALI THERAPEUTICS - TAKEDA, CO WILL SHARE GLOBAL PROFITS FROM COLLABORATION EQUALLY.DENALI THERAPEUTICS INC - TAKEDA HAS OPTION TO CO-DEVELOP AND CO-COMMERCIALIZE EACH OF THREE PROGRAMS.  Full Article

Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion
Friday, 15 Dec 2017 07:11am EST 

Dec 15 (Reuters) - TIGENIX NV ::REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE.‍FIRST ALLOGENEIC STEM CELL THERAPY TO RECEIVE POSITIVE CHMP OPINION IN EUROPE​.‍CX601 OFFERS POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WHO DO NOT RESPOND TO CURRENT AVAILABLE THERAPIES AND ARE SUBJECT TO NUMEROUS INVASIVE SURGERIES​.‍RECEIPT OF MA WILL TRIGGER A MILESTONE PAYMENT FROM TAKEDA TO TIGENIX OF EUR 15 MILLION​.  Full Article

Obsidian Therapeutics Announces $49.5 Mln Series A Financing To Develop Controllable Cell And Gene Therapy Products
Wednesday, 6 Dec 2017 06:15am EST 

Dec 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::OBSIDIAN THERAPEUTICS ANNOUNCES $49.5 MILLION SERIES A FINANCING TO DEVELOP CONTROLLABLE CELL AND GENE THERAPY PRODUCTS.OBSIDIAN THERAPEUTICS - SERIES A FINANCING LED BY GV, AND INCLUDED TAKEDA VENTURES, AMGEN VENTURES AMONG OTHERS.  Full Article

Takashimaya to acquire Tokyo-based real estate properties for 49.5 bln yen
Friday, 1 Dec 2017 02:22am EST 

Dec 1 (Reuters) - Takashimaya Co Ltd <8233.T>:Says it signs agreement with a wholly owned unit of Takeda Pharmaceutical Co Ltd <<<4502.T>>>, to acquire two Tokyo-based real estate properties as of the end of March 2019, at the price of 49.5 billion yen in total.  Full Article

Takeda Pharmaceutical unit signs agreement for sale of properties worth 49.5 bln yen
Friday, 1 Dec 2017 02:04am EST 

Dec 1(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says its wholly owned subsidiary Takeda Pharmaceutical Real Estate Company has signed an agreement with Takashimaya Company Limited for the sale of properties.Says the sale price is 49.5 billion yen.  Full Article

Deals of the day-Mergers and acquisitions

April 19 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday: ** Rare disease drug maker Shire Plc said it had rejected a $63 billion cash-and-stock acquisition offer by Japan's Takeda Pharmaceutical Co Ltd, while Allergan Plc reversed course on pursuing a rival bid. ** Austrian property group Immofinanz is putting its 26 percent stake in peer CA Immo on the block, it said, after a review of its strategic options.